Fresenius Kabi
Data integrity scuppers Fresenius deal with Akorn
However Fresenius could be liable to pay $129m in termination fees
Fresenius says Akorn investigation could affect takeover
External ‘experts’ are investigating alleged breaches of data integrity requirements
Fresenius Kabi buys Akorn and Merck’s biosimilar businesses
German-based firm predicts savings after it unites the two biopharma companies